Adenosine arrests breast cancer cell motility by A3 receptor stimulation
暂无分享,去创建一个
W. Junger | Yu Chen | C. Ledderose | Linglin Li | Jingping Zhang | T. Woehrle | Y. Bao | M. Hefti | Thomas Seier
[1] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.
[2] M. Aubry,et al. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma , 2016, Oncotarget.
[3] R. Broaddus,et al. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. , 2015, The Journal of clinical investigation.
[4] W. Junger,et al. Novel method for real‐time monitoring of ATP release reveals multiple phases of autocrine purinergic signalling during immune cell activation , 2015, Acta physiologica.
[5] G. Dubini,et al. Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation , 2014, Proceedings of the National Academy of Sciences.
[6] S. Jalkanen,et al. Adenosine Inhibits Tumor Cell Invasion via Receptor-Independent Mechanisms , 2014, Molecular Cancer Research.
[7] Luzhe Sun,et al. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis , 2014, Oncogene.
[8] L. Antonioli,et al. Immunity, inflammation and cancer: a leading role for adenosine , 2013, Nature Reviews Cancer.
[9] W. Junger,et al. Pannexin 1 Channels Link Chemoattractant Receptor Signaling to Local Excitation and Global Inhibition Responses at the Front and Back of Polarized Neutrophils* , 2013, The Journal of Biological Chemistry.
[10] P. Fishman,et al. CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. , 2012, The oncologist.
[11] N. Sträter,et al. Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.
[12] R. Merrill,et al. Risk-adjusted female breast cancer incidence rates in the United States. , 2012, Cancer epidemiology.
[13] M. Forghani,et al. Expression of A1 and A3 Adenosine Receptors in Human Breast Tumors , 2012, Tumori.
[14] Geoffrey Burnstock,et al. Purinergic signalling , 2012, Acta physiologica.
[15] E. Bulger,et al. Increased Neutrophil Adenosine A3 Receptor Expression Is Associated With Hemorrhagic Shock and Injury Severity in Trauma Patients , 2011, Shock.
[16] A. IJzerman,et al. Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine , 2011, Purinergic Signalling.
[17] M. Smyth,et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. , 2011, Cancer research.
[18] W. Junger,et al. Immune cell regulation by autocrine purinergic signalling , 2011, Nature Reviews Immunology.
[19] S. Fuqua,et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. , 2011, Cancer research.
[20] F. Di Virgilio,et al. The purinergic receptor P2Y2 receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation , 2010, Allergy.
[21] M. Smyth,et al. Extracellular adenosine triphosphate and adenosine in cancer , 2010, Oncogene.
[22] A. Schwab,et al. Autocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis , 2010, Science Signaling.
[23] W. Junger,et al. Purinergic Signaling: A Fundamental Mechanism in Neutrophil Activation , 2010, Science Signaling.
[24] F. Fernández‐Avilés,et al. Mechanisms by Which Adenosine Restores Conduction in Dormant Canine Pulmonary Veins , 2010, Circulation.
[25] M. Barrachina,et al. DNA methylation regulates adenosine A2A receptor cell surface expression levels , 2010, Journal of neurochemistry.
[26] M. Smyth,et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis , 2010, Proceedings of the National Academy of Sciences.
[27] Michael R. Elliott,et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.
[28] K. Watabe,et al. Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity , 2009, Neoplasia.
[29] P. Insel,et al. Ecto-nucleoside Triphosphate Diphosphohydrolase 1 (E-NTPDase1/CD39) Regulates Neutrophil Chemotaxis by Hydrolyzing Released ATP to Adenosine* , 2008, Journal of Biological Chemistry.
[30] A. Ohta,et al. Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia , 2008, Clinical Cancer Research.
[31] W. Junger,et al. Hypertonic saline up-regulates A3 adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis* , 2008, Critical care medicine.
[32] A. Zlotnik. New insights on the role of CXCR4 in cancer metastasis , 2008, The Journal of pathology.
[33] W. Junger. Purinergic regulation of neutrophil chemotaxis , 2008, Cellular and Molecular Life Sciences.
[34] Z. Ou,et al. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells , 2008, Journal of Cancer Research and Clinical Oncology.
[35] W. Junger,et al. A3 AND P2Y2 RECEPTORS CONTROL THE RECRUITMENT OF NEUTROPHILS TO THE LUNGS IN A MOUSE MODEL OF SEPSIS , 2007, Shock.
[36] M. Hoth,et al. P2X7 receptor stimulation upregulates Egr‐1 biosynthesis involving a cytosolic Ca2+ rise, transactivation of the EGF receptor and phosphorylation of ERK and Elk‐1 , 2007, Journal of cellular physiology.
[37] G. Burnstock,et al. Purine and pyrimidine receptors , 2007, Cellular and Molecular Life Sciences.
[38] Z. Ou,et al. Overexpression of Ecto-5'-Nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix , 2007, Cancer biology & therapy.
[39] Linda Yip,et al. ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.
[40] W. Gan,et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.
[41] A. Ohta,et al. A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.
[42] A. Richmond,et al. Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. , 2006, Cancer research.
[43] J. Sévigny,et al. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance , 2006, Purinergic Signalling.
[44] G. Kong,et al. The antitumor effect of LJ-529, a novel agonist to A3 adenosine receptor, in both estrogen receptor–positive and estrogen receptor–negative human breast cancers , 2006, Molecular Cancer Therapeutics.
[45] Seiko F. Okada,et al. Nucleotide Release Provides a Mechanism for Airway Surface Liquid Homeostasis* , 2004, Journal of Biological Chemistry.
[46] P. Insel,et al. A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors , 2004, Journal of leukocyte biology.
[47] P. Fishman,et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3β and NF-κB , 2004, Oncogene.
[48] G. Borisy,et al. Cell Migration: Integrating Signals from Front to Back , 2003, Science.
[49] P. Fishman,et al. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. , 2003, Anticancer research.
[50] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[51] B. Fredholm,et al. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.
[52] R. Hipskind,et al. Extracellular ATP activates multiple signalling pathways and potentiates growth factor-induced c-fos gene expression in MCF-7 breast cancer cells. , 2000, Carcinogenesis.
[53] R. K. Shepherd,et al. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. , 1997, The Journal of clinical investigation.
[54] J. Blay,et al. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. , 1997, Cancer research.
[55] G. Schatten,et al. Adhesion of cells to surfaces coated with polylysine. Applications to electron microscopy , 1975, The Journal of cell biology.
[56] B. Paradiso,et al. The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. , 2013, European journal of cancer.
[57] J. Sévigny,et al. Impact of ectoenzymes on p2 and p1 receptor signaling. , 2011, Advances in pharmacology.
[58] P. Fishman,et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. , 2008, International journal of oncology.
[59] F. Karami-Tehrani,et al. Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. , 2007, Oncology research.
[60] P. Fishman,et al. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. , 2004, Oncogene.